New Mountain Capital terminated a $32 billion deal to combine five of its health-tech portfolio companies into a new platform, Thoreau, led by its former executive Matt Holt. The firm scrapped the transaction after Holt’s revised offer introduced deferred payments and unresolved financing governance issues. The collapse demonstrates the high bar for complex secondary transactions, proving that even a compelling strategic thesis cannot overcome flawed deal mechanics and risks to limited partners, especially when involving departing leadership.
- Deal Name
- Proposed ‘Thoreau’ AI Health-Tech Platform
- Parties
- New Mountain Capital (Seller), Matt Holt (Buyer Lead)
- Transaction Type
- Internal asset sale / Secondary transaction
- Proposed Value
- $32 billion
- Proposed Debt Financing
- Over $12 billion
- Key Lenders
- JPMorgan, Goldman Sachs
- Portfolio Companies Involved
- Datavant, Swoop, Machinify, Smarter Technologies, Office Ally
- Collapsed Date
- Offer revision submitted Feb 27; termination announced shortly after
- Failure Mode
- Terminated negotiations before closing
- Root Cause
- Unacceptable changes to offer structure, deferred payments, and financing governance issues
New Mountain Capital has terminated complex negotiations for a marquee transaction, scrapping a proposed $32 billion deal that aimed to combine five of its high-growth healthcare technology portfolio companies under former President of Private Equity, Matt Holt. The decision, communicated to investors via a letter last week, signals the high bar private equity sponsors maintain for internal asset sales, particularly when faced with evolving deal terms and structural complexities.
Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:
đź’Ľ When Claude Code Marries Due Diligence!
The ambitious transaction, which would have created a substantial new entity named Thoreau, intended to merge companies holding valuable positions in data, AI, and administrative efficiency within the U.S. healthcare ecosystem. While the deal failed to close, the underlying thesis of creating a unified platform aligns precisely with current market priorities.
The Vision: Consolidating AI-Driven Healthcare Assets
The proposed platform sought to leverage artificial intelligence to reduce soaring healthcare costs by integrating disparate capabilities across the payer, provider, and data layers. The five portfolio companies slated for combination were:
- Datavant: Focused on secure data connectivity and linking clinical and claims data for research and operations.
- Swoop: Providing payment and invoicing technology, initially targeting SMBs.
- Machinify, Smarter Technologies, and Office Ally: Contributing to AI-driven workflow, revenue cycle management, and practice administration tools.
This strategy of platform-plus-add-on strategies remains dominant in the sector, as firms seek to build scalable entities with predictable revenue streams in the shift toward value-based care models. The proposed combination, if completed, would have ranked among the largest private equity-backed health tech formations in recent memory.
Visualizing the Proposed Platform Assets
| Portfolio Company | Reported Core Function |
|---|---|
| Datavant | Secure Healthcare Data Connectivity |
| Swoop | Payment & Invoicing Technology |
| Machinify / Smarter Technologies | AI Workflow / Revenue Cycle Management |
| Office Ally | EHR & Practice Management Tools |
Anatomy of the Deal Breakdown: Governance and Financing Hurdles
The failure to close was attributed to a protracted negotiation process and material changes in the final offer structure. New Mountain informed investors that Holt missed an initial deadline for finalizing the offer, and a subsequent revision submitted on February 27 introduced significant hurdles.
The primary concerns cited by New Mountain centered on deal financing governance issues and structure, a critical area for LPs assessing large secondary transactions:
- Deferred Payments: The revised proposal introduced a mechanism that deferred payment of “several billion dollars” of the purchase price, shifting risk and timing.
- Financing Structure: Unresolved concerns remained regarding the underlying debt structure for the massive transaction.
- Distraction: The firm noted the prolonged process had become an “increasing burden and distraction” to management and portfolio company decision-making.
Financing for the deal was substantial, reportedly including over $12 billion in debt commitments from major institutions like JPMorgan and Goldman Sachs, alongside equity contributions. A subsequent proposal involving ICG Strategic Equity, intended to rectify some payment and governance issues, was also ultimately rejected.
The Path Forward: Strategy Endures Without the Executive
Despite scrapping the specific structure led by Holt, New Mountain affirmed its commitment to the underlying strategic objective. The firm indicated it “may still pursue the strategy of combining some of the healthcare technology companies” but without Holt’s involvement. This suggests that the firm sees continued value in building an integrated digital health platform, a trend favored by sponsors in 2026 seeking tech-enabled services with resilient revenue.
For executive deal advisors, this situation offers a stark reminder of the risks associated with large-scale management buyouts or secondary sales involving departing senior leadership. While Holt has launched his new venture, Thoreau, New Mountain’s decisive action underscores the fiduciary duty to protect fund interests over facilitating a complex transition. The ability to execute a smooth internal asset combination or explore private equity exit strategies in SaaS/HealthTech is paramount for sustaining fund performance narratives.
Sources
privateequitywire.co.uk privateequityinternational.com tradingview.com livemint.com medcitynews.com bloomllc.com towardshealthcare.com fiercehealthcare.com kpmg.com cbh.com
